Search

Displaying results 3161 - 3170 of 10000 in total
  1. Drug

    Methamidophos

    go.drugbank.com/drugs/DB14972
    Experimental

    Leukemia in First Remission). … Methamidophos is under investigation in clinical trial NCT03223753 (Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Lumefantrine

    go.drugbank.com/drugs/DB06708
    ApprovedInvestigational

    Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

  3. Drug

    Hexocyclium

    go.drugbank.com/drugs/DB06787
    Approved

    Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. … Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more

  4. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    The partial clinical hold was later lifted in May 2021. … [A254192] Odronextamab received its first approval in the European Union on August 26, 2024, for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma

  5. Drug

    Sincalide

    go.drugbank.com/drugs/DB09142
    Approved

    Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. … When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract.

  6. Drug

    Dimethyl sulfone

    go.drugbank.com/drugs/DB14090
    Investigational

    Mixtures: flexijoint 3-in-1 Joint Care Powder, OSTEOACTIV 3-in-1 Joint Formula PowderProducts: Nn Bio-MSM 750
  7. Drug

    Sapropterin

    go.drugbank.com/drugs/DB00360
    ApprovedInvestigational

    Sapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. … It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of

  8. Target

    Deoxyhypusine hydroxylase

    go.drugbank.com/bio_entities/BE0018877
    TargetHumans

    Catalyzes the hydroxylation of the N(6)-(4-aminobutyl)-L-lysine intermediate produced by deoxyhypusine synthase/DHPS on a critical lysine of the eukaryotic translation initiation factor 5A/eIF-5A. This is the second step of the post-tran...

    Synonyms: HEAT-like repeat-containing protein 1
  9. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen. … A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour cells in

  10. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    It was granted approval by FDA in August 2017 under the market name Kymriah. … In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent